News & Updates

Sticking to a diet that follows the American dietary guideline recommendations may forestall the potential for low-grade prostate cancer to progress to high-grade disease, as suggested in a study.

Individuals with psoriasis creeping into their intimate areas may find relief from apremilast, as shown by the week-32 improvements in multiple disease parameters in the phase III DISCREET study.

Older men who have had prostate-specific antigen (PSA) testing and are approaching the age limit for recommended screening appear to have a relatively low risk of developing metastatic or fatal prostate cancer, suggests a recent study.

In a preplanned interim analysis of the NIAGARA trial, the addition of durvalumab to neoadjuvant chemotherapy prior to radical cystectomy (RC) and durvalumab monotherapy following surgery confers a survival advantage over chemo alone for muscle-invasive bladder cancer (MIBC).

Darolutamide plus androgen-deprivation therapy (ADT), without docetaxel, improves radiological progression-free survival (rPFS) and secondary efficacy outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to results of the global phase III ARANOTE trial presented at ESMO 2024.